Pediatric demyelinating diseases: Multiple sclerosis or not?

Israel Medical Association Journal

Volumn 14, Issue 4, 2012, Pages 251-253

  Vaknin Dembinsky, Adi ^a   Karussis, Dimitrios ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acute disseminated encephalomyelitis (ADEM); Expert consortiums; Magnetic resonance imaging (MRI); Multiple sclerosis (MS)

Indexed keywords

IMMUNOMODULATING AGENT;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; CHILD; CIGARETTE SMOKE; CLINICAL FEATURE; DEMYELINATING DISEASE; DEVELOPMENT; DISABILITY; EDITORIAL; GROWTH; HUMAN; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; RISK FACTOR; SIDE EFFECT; VIRUS INFECTION; VITAMIN D DEFICIENCY;

FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 84860311454     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68: S7-12.
2. Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol 2011; 26: 675-82.
3. Ghezzi A, Banwell B, Boyko A, et al. The management of multiple sclerosis in children: a European view. Mult Scler 2010; 16: 1258-67.
4. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
5. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
6. Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18 (1): 116-27.
7. Verhey LH, Branson HM, Shroff MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011; 10: 1065-73.
8. Tenembaum SN. Emerging concepts in pediatriconset multiple sclerosis and related disorders. Curr Opin Pediatr 2010; 22: 726-30.
9. Achiron A, Garty B-Z, Menascu S, et al. Multiple sclerosis in Israeli children: incidence, and clinical, cerebrospinal fluid and magnetic resonance imaging findings. IMAJ 2012; 14: 234-9.
10. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6: 887-902.
11. Jacobs LD, Beck RW, Simon JH, et al. Intra muscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
12. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
13. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-97.